Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

 Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop Novel Immuno-Oncology Therapies

Shots:

  • NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs
  • The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology
  • FIND-IO platform has ability to identify cell surface molecular interactions while converting them into disease modifying immunotherapies

Click here to read full press release/ article | Ref: Eli Lilly | Image: Biospace

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post